Panelists discuss how the data from the BRAVE-AA1 and BRAVE-AA2 phase 3 trials demonstrated the safety and efficacy of baricitinib, leading to its FDA approval in 2022 as the first systemic treatment ...

The study confirmed that ritlecitinib was well tolerated among participants, making it a potential candidate for systemic therapy in alopecia areata[2]. In addition to these specific treatments ...

The global alopecia treatment market size was valued at USD 3.48 billion in 2024 and is projected to reach from USD 3.62 billion in 2025 to USD 5.20 billion by 2033, growing at a CAGR of 4.1% during ...

HCW Biologics gets US FDA nod to begin first-in-human phase 1 trial of HCW9302 to treat patients with moderate-to-severe alopecia areata: Miramar, Florida Wednesday, February 5, 2 ...

HCW Biologics shares are trading higher on Monday after the company announced clearance from the Food and Drug Administration ...

An autoimmune condition known as alopecia areata affects the hair follicles, leading to hair loss, breakage, and complete baldness. Hormonal changes, genetic disorders, head radiation therapy ...

Stress can lead to noticeable hair loss, usually months after a stressful situation occurs. This type of hair loss is ...

Superficial cryotherapy is a novel cold-based treatment that has emerged as a potential therapy for patchy alopecia areata ...

Alys Pharmaceuticals, Inc. (“Alys”), an immune-dermatology focused company, today announces that the U.S. Food and Drug Administration (FDA) and Health Canada have cleared the Investigational New Drug ...

The risk for alopecia areata is increased among patients with lower serum levels of vitamin D and zinc, but no relationship was observed with copper.

Wong, Founder and CEO of HCW Biologics, commented, “The FDA’s clearance to initiate our first-in-human clinical trial for HCW9302 brings us one step closer to advancing a potentially transformative ...